TRT Delivery Methods
Complete Comparison, IM, SubQ, Gel, Pellets, Patch, Oral, Buccal, and Nasal
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Multiple FDA-approved formulations; routes differ in label and warnings
- WADA
- Prohibited (S1 Anabolic Agent)
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about trt delivery methods in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
A detailed comparison of the routes used to deliver testosterone: intramuscular and subcutaneous injection (cypionate, enanthate, propionate), transdermal gels (AndroGel, Testim, Fortesta, Vogelxo), subcutaneous pellets (Testopel), the Androderm patch, oral undecanoate (Jatenzo, Kyzatrex), buccal Striant, and nasal Natesto. Each route trades convenience against kinetic stability, transfer risk, monitoring burden, and, importantly, whether a dose can be corrected once given.
Every route delivers testosterone, they differ in kinetics, monitoring, transfer risk, and how easily a dose can be corrected.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
All routes raise serum testosterone, but pharmacokinetics differ markedly. Injectable esters (cypionate, enanthate) produce a peak after dosing followed by a trough; biweekly dosing exaggerates the peak-trough swing and can make mood and libido fluctuate, which is why many clinicians favor weekly or more frequent dosing. Subcutaneous injection uses a smaller needle (25-27G vs 21-23G IM) and tends to produce lower peaks and steadier levels. Transdermal gels deliver daily, avoid first-pass liver metabolism, but carry transfer risk and variable absorption. Pellets provide months of release with no daily compliance but cannot be titrated after implantation. Oral undecanoate is absorbed via the lymphatics with food, bypassing first-pass liver toxicity that plagued older oral androgens. Nasal testosterone is unusual in preserving the gonadotropin axis.
How it is taken
Physiological replacement targets the mid-normal range, typically 100-200 mg/week of injectable cypionate or enanthate (often split into smaller, more frequent doses), 50-100 mg/day for gels, or twice-daily oral undecanoate with food. Doses are titrated to trough total testosterone and symptoms, not to a 'feel-better' ceiling. Pellets are dosed at implantation and cannot be adjusted until they dissolve.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks. Changes to hormones, sexual function, or sexual health warrant evaluation by a qualified healthcare provider.
Replacement is not the same as a cycle
Route does not change the substance, testosterone cypionate is testosterone cypionate. What separates replacement from anabolic use is dose and resulting serum level. A common telehealth dose of 200 mg/week can push a man who was not deficient well above 1500 ng/dL, which is supraphysiological regardless of route.
What it does to fertility
All exogenous testosterone routes except nasal (Natesto) substantially suppress LH and FSH and therefore spermatogenesis, causing testicular atrophy and potential infertility. Natesto's short-acting nasal kinetics better preserve the gonadotropin axis and fertility, a genuine advantage for men who want to maintain fertility, though long-term data are limited.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Trough total testosterone (timed to route) at 3-6 months then annually
- Hematocrit / CBC at 3-6 months (polycythemia risk)
- PSA at 3-6 months if over 40, then annual prostate monitoring
- Blood pressure (especially oral undecanoate)
- Lipid panel (testosterone can lower HDL)
- Estradiol if gynecomastia or aromatization symptoms
What people get wrong
Often saidPellets are 'set it and forget it' with no downside
ActuallyThe inability to titrate after implantation is a real clinical limitation, if the dose is too high you must wait months for the pellet to dissolve. Extrusion (~5%), insertion-site pain, and infection are documented and underdisclosed in direct-to-consumer marketing.
Who profits, and who pushes back
Bradley Anawalt, MD
Cautions that route choice matters less than confirming genuine hypogonadism first, and warns that convenience-driven prescribing and supraphysiologic dosing outrun the evidence.
Endocrine Society guideline panel
Recommends individualizing route to patient preference and monitoring burden, and stresses that no delivery method substitutes for a confirmed diagnosis and proper follow-up of hematocrit and prostate parameters.
Pharmacokinetic reviewers
Note that large peak-trough swings from infrequent intramuscular dosing can drive mood and libido fluctuation, and that head-to-head outcome data favoring one route over another remain limited.
Set against the alternatives
No single route is best for everyone; each trades convenience against control. Injectables are cheapest and most flexible but require self-injection and can swing between peak and trough unless dosed frequently; subcutaneous injection softens those swings with a smaller needle. Gels give steady daily levels and easy titration but carry secondary-transfer risk and variable absorption. Pellets remove daily compliance for months but cannot be adjusted or quickly stopped once implanted. Oral undecanoate avoids needles and the old hepatotoxicity of 17-alpha-alkylated androgens but needs food and twice-daily dosing. Nasal testosterone is unique in largely sparing the LH/FSH axis, making it the most fertility-friendly option, at the cost of multiple daily applications.
| Route / Formulation | Frequency | Key feature / drawback | FDA status |
|---|---|---|---|
| IM cypionate / enanthate (Depo-Testosterone, generic) | Weekly-biweekly | Established, cheap; peak-trough swings (worse if biweekly) | Approved |
| Subcutaneous injection (same esters) | Weekly | Smaller needle, steadier levels, equivalent efficacy | Approved/widely used |
| Transdermal gel (AndroGel 1% & 1.62%, Testim, Fortesta, Vogelxo) | Daily | No-needle; transfer risk to women/children; variable absorption | Approved |
| Pellets (Testopel, compounded) | Every 3-6 months | No daily burden; cannot titrate after implant; ~5% extrusion | Approved (Testopel) |
| Patch (Androderm) | Nightly | High skin-irritation rate; little used since gels | Approved |
| Oral undecanoate (Jatenzo, Kyzatrex) | Twice daily with food | No injection/transfer; raises BP (FDA warning); food-dependent | Approved (2019/2022) |
| Buccal (Striant) | Twice daily | Gum adhesion; gum irritation common; limited use | Approved |
| Nasal (Natesto) | Twice/thrice daily | Preserves LH/FSH and fertility; limited long-term data | Approved |
What we do not know
- Do steadier-kinetics routes (SubQ, gel, nasal) yield better symptom or safety outcomes than peak-trough intramuscular dosing in head-to-head trials?
- How much does route choice affect erythrocytosis risk independent of achieved testosterone level?
- Can nasal testosterone reliably preserve spermatogenesis well enough to be a fertility-sparing standard?
- What is the real-world magnitude of inadvertent gel transfer to partners and children under current labeling?
- Do long-acting routes like pellets and injectable undecanoate carry hidden risk because a dose cannot be rapidly withdrawn?
What could change
Oral undecanoate uptakeNewer FDA-approved oral options (Jatenzo, Kyzatrex, Tlando) expanding needle-free choiceFertility-sparing emphasisGrowing interest in nasal testosterone and adjuncts that preserve the gonadotropin axisPost-TRAVERSE positioning2023 safety data and 2025 label changes may shift route counseling and willingness to treatLong-acting injectablesInterest in extended-interval depot dosing balanced against non-retrievability concernsAuto-injectors and devicesPatient-friendly subcutaneous delivery devices aimed at improving adherence
At a glance
- Most common US injectable
- Testosterone cypionate
- Typical TRT dose
- 100-200 mg/week IM physiological replacement
- Gel transfer risk
- Driver of the historical transdermal black-box
- Pellet duration
- 3-6 months, not titratable once implanted
- Fertility-sparing route
- Nasal (Natesto) preserves LH/FSH
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about TRT Delivery Methods. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Subcutaneous vs intramuscular testosterone studies2010s
Multiple studies show SubQ delivers equivalent efficacy with steadier serum levels and improved tolerability vs IM, supporting growing clinical preference for the SubQ route